Search
Major research funding calls are out now
First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.
Read moreChairs and Members
ChairJane Apperley
Co-chairAndreas Hochhaus
Executive Board members (2021–2027 term)
Prof Nicholas CP Cross, University of Southampton (UK)
Prof Oliver Hantschel, University of Marburg (Germany)
Dr Delphine Rea, University of Paris (France)
Dr Katerina Machova Polakova, Institute of Hematology and Blood Transfusion, Prague; Charles University (Czech Republic)
Prof…
Chairs and Members
Chair:
Prof Arnon Kater (2021-2024)
Amsterdam University Medical Centers, University of Amsterdam
The Netherlands
Co-chair:
Prof Dr Sarka Pospisilova (2021-2024)
Masaryk Univerzity and Univerzity Hospital Brno
Czech Republic
SWG Executive Board members:
Carol Moreno (Hospital Sant Pau, Barcelona, Spain)
Richard Rosenquist (Karolinska Institute, Stockholm, Sweden)
Andy Rawstron (HMDS, Leeds, UK)
Yair Herishanu…
COST Action ‘EuNet-INNOCHRON’
The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.
Read moreDr A van Hylckama Vlieg Announced Winner of the first EHA-ISTH Joint Fellowship
The award of EUR 72,000 over two years is intended to support the study of the physiology of bleeding, coagulation or thrombosis. Dr.
Read moreChairs and Members
Chair (until 2026)Hermann Einsele, Professor of Hematology and Oncology, University Hospital Würzburg (Germany)
Co-chair (until 2026)Arjan van de Loosdrecht, Professor of Hematology and Immunhematology, Amsterdam UMC (The Netherlands)
SWG Steering Committee members
Jorge Sierra, Professor of Hematology, Hospital Santa Creu I Sant Pau…
First randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreHematology Tutorials
Hematology Tutorials are courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders.
Read moreI4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read more